It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The executive leadership over at Moderna is abandoning ship in terms of what the future holds for its Wuhan coronavirus (COVID-19) vaccine.
Both Stéphane Bancel, its CEO, and Tal Zaks, its CMO (chief medical officer) have cashed out their company shares as the company’s plandemic jab is right on the verge of entering late-stage trials.
According to Securities and Exchange Commission (SEC) filings, Zaks recently offloaded nearly all of his shares, while Bancel has tossed many of his over the past several months. Zaks, however, still holds tens of thousands of dollars’ worth of options in the company.
originally posted by: pravdaseeker
Worse than a hoax, this vaccine will clearly harm large numbers of people, given that 100% of study subjects are already experiencing adverse events in the high dose group, during the second round of injections. How toxic is this going to get during a third vaccine? Or a fourth? And is there any end to how many injections of the same vaccine will be mandated by a corrupt, criminal FDA, CDC and national media that makes all its editorial decisions based on the profit demands of the drug cartels?
Finally, keep in mind that globalists who also promote the depopulation agenda are demanding this vaccine be given to Black people first. So wait: Take a toxic vaccine that doesn’t work but that causes huge side effects, and line up all the Blacks to be human guinea pigs?
Sounds like globalists and the vaccine industry have a whole new plan for planet Earth beyond 2020, and it has nothing to do with halting the pandemic but everything to do with genocide.
According to Securities and Exchange Commission (SEC) filings, Zaks recently offloaded nearly all of his shares, while Bancel has tossed many of his over the past several months. Zaks, however, still holds tens of thousands of dollars’ worth of options in the company.
According to Securities and Exchange Commission (SEC) filings,